Respiratory Diseases

GSK and Empirico enter license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases - GSK [Visit Site | Read More]

GSK pens $745M deal for phase 1 drug that hits sweet spots of COPD, oligonucleotides - Fierce Biotech [Visit Site | Read More]

Chronic respiratory diseases in the WHO European Region - World Health Organization (WHO) [Visit Site | Read More]

Respiratory disease profile: statistical commentary, June 2025 - GOV.UK [Visit Site | Read More]

New COPD Subtype Discovered - respiratory-therapy.com [Visit Site | Read More]